Business
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan ...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n Reimbursement for Vascepa in\n \n Canada\n \n is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-label\n \n \n \n \n Public reimbursement for Vascepa is now available in\n \n Ontario\n \n ,\n \n Quebec\n \n ,\n \n New Brunswick\n \n ,\n \n Northwest Territories\n \n and for the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit\n \n \n peoples\n \n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n July 25, 2022\n \n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it has entered into a Product Listing Agreement (\"PLA\") with\n \n Ontario\n \n , for the listing and public reimbursement of Vascepa (icosapent ethyl) on the province's Public Prescription Drug Insurance Plan. The PLA with\n \n Ontario\n \n is effective\n \n July 21, 2022\n \n .\n \n \n Under the terms of the PLA, Vascepa will be reimbursed for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.\n \n \n \"We are pleased to build on the PLA agreements signed to-date, which now include\n \n Ontario, Canada's\n \n largest province by population, and\n \n Quebec\n \n , which is the second largest,\" said\n \n Gilbert Godin\n \n , CEO of HLS. \"The public reimbursement agreements for Vascepa that have been signed so far represent more than 65% of Canadians covered by a public plan, which brings us closer to universal access for the product since private coverage is already in excess of 95% for those in-label. This should accelerate the momentum already in place with physicians who, in increasing nu...